NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy
- Author(s)
- Bazinet, A; Ferrajoli, A; Jain, N; Burger, JA; Yilmaz, M; Swaminathan, M; Kantarjian, HM; Keating, M; Thompson, PA; Wierda, WG;
- Journal Title
- Blood Advances
- Publication Type
- Online publication before print
- Abstract
- We performed next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment in 17 patients with chronic lymphocytic leukemia (CLL) in remission at a median of 15.7 years post fludarabine, cyclophosphamide, and rituximab (FCR) and identified persistent MRD in 13/17 (76%) patients.
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2026020243
- Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2026020243- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-04-02 12:29:59
Last Modified: 2026-04-02 12:30:07